Lipid Modulating Agents

• What are Therapeutic Market Outlooks?
• Available Reports
• Pricing and Deliverables
• TMO Sample Pages

Tables and Figures - Lipid Modulating Agents

• Page 3: Lipoprotein Patters (Fredrickson Phenotypes)
• Page 5: LDL-C Goals by Patient Segment
• Page 5: HDL-C Guidelines
• Page 5: Triglyceride Treatment Thresholds
• Page 6: NHANES Estimates of Cholesterol Percentiles
• Page 6: 2006-2013 Projection: Addressable Population, Treated Population and Patient Years of Therapy
• Page 7: Potency for Major Existing and Pipeline Drugs
• Page 7: Dyslipidemia Patient Population Model
• Page 8: U.S. Treated Dyslipidemia Population in Million
• Page 11: U.S. Statins Market Model, 2004-2013
• Page 12: U.S. Statins Market Model, 2004-2013, continued
• Page 13: Treatment Decision Tree: Primary Prevention
• Page 14: Treatment Decision Tree: Secondary Prevention
• Page 15: Physician Product Ratings
• Page 16: AVOS Physician Panel Market Trend Forecasts
• Page 18: Marketed Products in the United States
• Page 19: Timeline of Major Market Events
• Page 21: Lipitor Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 22: Lipitor Cumulative NRx Change, Cumulative TRx Change
• Page 23: Zetia/Vytorin Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, Commercial Strength, and Vytorin NRx and TRx
• Page 26: Crestor Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecast,s and Commercial Strength
• Page 29: Zocor/Simvastatin Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecast,s and Commercial Strength
• Page 31: Pravachol/Pravastatin Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 33: Lescol/Lescol XL Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 34: Tricor Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecast,s and Commercial Strength
• Page 36: Niaspan/Advicor Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 38: Caduet Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 40: Atorvastatin Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts; Atorvastatin Lipitor U.S. Market Share Forecasts and U.S. Revenue Forecasts
• Page 42: MK-0524A/MK-0524B Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 44: Simcor Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 46: ABT-335/Crestor + ABT-335 Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 48: TAK-475 Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and TAK-475/Atorvastatin LDL-C/HDL-C Chart
• Page 50: Clinical Success Rates of Lipid Modulating Agents: 1990-Present
• Page 52: Drugs in Development